By Unknown Author
Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products.
Published: October 7, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1OWF2wY
from WordPress http://ift.tt/1MbQEdY
via Hadi Aboukhater
No comments:
Post a Comment